Italia markets closed

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
66,00+0,63 (+0,96%)
In data: 01:51PM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente65,37
Aperto65,54
Denaro65,85 x 100
Domanda66,14 x 100
Min-Max giorno64,98 - 66,03
Intervallo di 52 settimane50,27 - 67,36
Volume651.221
Media Volume3.641.793
Capitalizzazione13,003B
Beta (mensile su 5 anni)0,74
Rapporto PE (ttm)20,00
EPS (ttm)3,30
Prossima data utili30 lug 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A71,77
  • GlobeNewswire

    Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

    PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

  • GlobeNewswire

    Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

    MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto